Spinal Cord Stimulation in Heart Failure

Heart Failure Clinical Trial

Official title: The Treatment of Spinal Cord Stimulation in Severe Heart Failure

Status Not yet recruiting

Clinical Trial Summary

Previous studies have shown that spinal cord stimulation (SCS) may improve cardiac output and decrease the risk of ischemic ventricular arrhythmia in animal model and its safety profile in human trial. The purposes of this study are to evaluate the feasibility, treatment efficacy and safety of SCS in patients with severe symptomatic heart failure (HF).

Clinical Trial Description

Morbidity and mortality in heart failure (HF) patients remain high, even with recent advances in therapies. Previous studies have shown that the autonomic nervous system plays an important role in the pathophysiology of HF and sudden cardiac death.

Spinal cord stimulation (SCS) is a neurostimulation therapy, which involves the stimulation of selected nerve fibers and intends to create end-organ responses characterized by changes in blood flow, decrease of catecholamines and reduction in inflammation. The SCS system consists of an implantable pulse generator (IPG) and dual leads. Each lead has electrodes on the distal end. Electrical impulses travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation. By virtue of its potential in augmenting blood flow, decreasing catecholamines and reducing inflammation, SCS may benefit HF patients. ;

Related Conditions & MeSH terms

• Heart Failure

• NCT number: NCT03060148
• Study type: Interventional
• Source: Chang Gung Memorial Hospital
• Contact: Chun-Li Wang, MD
• Phone: +886975368158
• Email: wang3015@cgmh.org.tw
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 2017
• Completion date: June 2019